Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
RMD Open
|
January 5, 2018
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, et al.
Health and Quality of Life Outcomes
|
December 8, 2017
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
Elizabeth D Bacci, Amy M DeLozier, Chen-Yen Lin, et al.
RMD Open
|
July 19, 2022
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
Jürgen Braun, Uta Kiltz, Atul Deodhar, et al.
Clinical and Experimental Rheumatology
|
June 24, 2020
Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis
Ana-Maria Orbai, Dafna D Gladman, Hitoshi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy
Susan Halabi, Andrew J Armstrong, Oliver Sartor, et al.
Clinical and Experimental Rheumatology
|
December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
Arthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
The Journal of Dermatological Treatment
|
May 21, 2020
Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective
Neil J Korman, William Malatestinic, Orin M Goldblum, et al.
Annals of the Rheumatic Diseases
|
May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
Arthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer
Susan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.
Health and Quality of Life Outcomes
|
December 7, 2017
Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis
Elizabeth D Bacci, Amy M DeLozier, Chen-Yen Lin, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
RMD Open
|
January 5, 2018
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, et al.
Health and Quality of Life Outcomes
|
December 8, 2017
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
Elizabeth D Bacci, Amy M DeLozier, Chen-Yen Lin, et al.
RMD Open
|
July 19, 2022
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
Jürgen Braun, Uta Kiltz, Atul Deodhar, et al.
Clinical and Experimental Rheumatology
|
June 24, 2020
Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis
Ana-Maria Orbai, Dafna D Gladman, Hitoshi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy
Susan Halabi, Andrew J Armstrong, Oliver Sartor, et al.
Clinical and Experimental Rheumatology
|
December 18, 2018
Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
Arthur Kavanaugh, Helena Marzo-Ortega, Ronald Vender, et al.
The Journal of Dermatological Treatment
|
May 21, 2020
Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient's perspective
Neil J Korman, William Malatestinic, Orin M Goldblum, et al.
Annals of the Rheumatic Diseases
|
May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
Arthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer
Susan Halabi, Chen-Yen Lin, W Kevin Kelly, et al.
Health and Quality of Life Outcomes
|
December 7, 2017
Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis
Elizabeth D Bacci, Amy M DeLozier, Chen-Yen Lin, et al.
Page
of 5